Display:
Providers:
Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapeutics. The Company's lead product candidate, TP-03, is an investigational eye drop in Phase III to treat blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Blepharitis (Blephar is a reference to eyelid and itis is a reference to inflammation) is a condition characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes, which are pathognomonic for Demodex blepharitis. The Company designed TP-03 to target and eradicate the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of TP-03, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels.
|
|
|
|
|
Yesterday's News, August 11, 2022 | ||
---|---|---|
August 05, 2022 | ||
July 25, 2022 | ||
May 27, 2022 | ||
Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.
Copyright © 2022. All rights reserved.